Tuesday - KeyBanc Capital Markets has initiated coverage on GitLab Inc (NASDAQ:GTLB), assigning an Overweight rating with a price target of $70.00 for the shares. The firm\'s analysis suggests that GitLab, a company that operates as an independent DevSecOps platform, is poised for sustained mid-20% growth. This projection is based on the current stable-to-improving spending...
By Kevin Buckland TOKYO (Reuters) -The yen weakened and Japanese government bond yields fell after the Bank of Japan on Tuesday announced an exit from years of ultra-easy monetary policies, marking a historic shift from a decades-long fight against deflation. The Nikkei share average rose, reversing morning losses, following volatile trading immediately after the central...
On Tuesday, Guggenheim initiated coverage on DXC Technology stock (NYSE: NYSE:DXC), assigning a Neutral rating. The firm\'s analysis pointed to the challenges faced by the new management team, which has taken over an organization experiencing secular declines. The report acknowledged the potential for improvement under the new leadership but noted that such turnarounds are typically...
Tuesday, Guggenheim initiated coverage on Perficient stock (NASDAQ:PRFT), a digital consultancy firm, with a Neutral rating and a price target of $65.00. The firm recognized the company\'s high-value consulting-led approach and potential for margin expansion as it shifts more work offshore. The analyst noted that while Perficient\'s strategy for margin growth through a mix-shift in...
On Tuesday, Infosys Technologies (NYSE:NS:INFY) received a new stock coverage from Guggenheim, starting with a Neutral rating and a price target set at $20.00. The firm\'s decision is based on a balanced risk-reward scenario, as indicated by their analyst. The analysis highlights that the rationale behind the Neutral rating is Infosys\' potential for large deal...
(Reuters) - Haleon said on Tuesday top shareholder Pfizer (NYSE:PFE) offloaded a roughly $3.9 billion stake in the consumer healthcare firm, bringing down its holding in the British company to 22.6%. Pfizer previously held a 32% stake, followed by second-largest shareholder GSK which has a 4.2% holding. WHY IT'S IMPORTANT This is Pfizer\'s first stake...
By Yadarisa Shabong (Reuters) -AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The deal is AstraZeneca (NASDAQ:AZN)\'s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up...
On Tuesday, Guggenheim initiated coverage on TaskUs, Inc stock(NASDAQ:TASK) with a Neutral rating and a price target set at $13.00. The firm\'s analysis suggests that while TaskUs is positioned to return to year-over-year revenue growth, the current risk and reward dynamics are evenly balanced. The new coverage reflects an evaluation of TaskUs\'s potential to generate...
Tuesday, Guggenheim initiated coverage on Globant S.A. stock (NYSE: GLOB), a company specializing in digital and technology services, with a Buy rating and a price target of $250. The firm highlighted Globant\'s resilience in the face of macroeconomic uncertainties and its strong customer relationships and Studio model as key drivers for the company\'s future growth....
The Japanese yen weakened against other major currencies in the Asian session on Monday, as traders speculate over an end to the Bank of Japan\'s negative interest rate policy this week. The positive wage data and sticky inflation reports from the nation had spurred traders to speculate the BOJ will end its ultra-loose policies, at...